Mission:
Contributes to transition:
Contributes to SDG(s):
Cancer is a major and rapidly growing social problem: the number of cancer cases is expected to increase by 70% in the next twenty years. Immunotherapy can be very effective, but it does not work for everyone. Results are currently lacking in approximately 50% of patients receiving immunotherapy, while the therapy would probably benefit approximately 15% of non-selected patients.
Ellogon’s CE-IVDD certified solution EIDOSTM uses AI to pre-select ‘suitable’ patients for immunotherapy. The solution is easy and seamless to integrate into clinical practice.
“ROM InWest is investing in Ellogon because the company is accelerating digitalization in healthcare with AI innovations such as EIDOSTM,” explains Janet Nieboer, CEO of ROM InWest. “In doing so, they are contributing to sufficient available and affordable healthcare for everyone.”
DOPS transformeert afval naar nieuwe waardevolle grondstoffen zonder noemenswaardige CO2-uitstoot.
Confocal.nl: groundbreaking microscope technology for research in living cells
Tiny Library believes that parents should be able to rent baby supplies easily and affordably instead of buying them, so that we all have to buy far fewer new items.
Subscribe to our newsletter and stay up to date with news, stories, relevant events and more.
